Thrombotische Mikroangiopathien

Schlüsselwörter

thrombotische Mikroangiopathie - thrombotisch-thrombozytopenische Purpura - hämolytisch-urämisches Syndrom - Plasmapherese - Rituximab - Eculizumab

Keywords

thrombotic microangiopathy - thrombotic thrombocytopenic purpura - hemolytic uremic syndrome - plasma exchange - rituximab - eculizumab

• Literatur

• 1 Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2013; 33: 27-45
• 2 Crawley JTB, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Hematol Educ Program 2013; 2013: 292-299
• 3 Hie M, Gay J, Galicier L et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center. Blood 2014; 124: 204-210
• 4 Holz JB. The TITAN trial – assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transfus Apher Sci 2012; 46: 343-346
• 5 Karpman D. Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. Nephrol Dial Transplant 2012; 27: 3669-3674
• 6 Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost 2014; 40: 493-502
• 7 Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med 2013; 368: 2169-2181
• 8 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687
• 9 Plaimauer B, Kremer Hovinga JA, Juno C et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011; 9: 936-944
• 10 Roumenina LT, Loirat C, Dragon-Durey MA et al. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365: 8-26
• 11 Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014; 164: 759-766
• 12 Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335
• 13 Starck M, Wendtner CM. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol 2014; 164: 894-896
• 14 Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013; 126: 200-209
• 15 Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657